3-(2-Hydroxyphenyl)-5-(4-chlorophenyl)-pyrazol | 38371-80-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(2-Hydroxyphenyl)-5-(4-chlorophenyl)-pyrazol
• 英文别名: IA-49；2-[3-(4-chlorophenyl)-1H-pyrazol-5-yl]phenol
• CAS: 38371-80-1
• 化学式: C₁₅H₁₁ClN₂O
• 分子量: 270.718
• InChiKey: ZXVNJVRABSCRGU-UHFFFAOYSA-N

物化性质

• 熔点：
  206 °C(Solv: acetic acid (64-19-7))
• 沸点：
  498.0±35.0 °C(Predicted)
• 密度：
  1.340±0.06 g/cm3(Predicted)
• 溶解度：
  <0.3 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  48.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  三光气 、 3-(2-Hydroxyphenyl)-5-(4-chlorophenyl)-pyrazol 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以63%的产率得到2-(4-chlorophenyl)pyrazolo<1,5-c><1,3>benzoxazin-5-one
  参考文献：
  名称：

  新型吡唑并 [1,5-c] [1,3] 苯并恶嗪的构效关系研究：合成和苯二氮卓受体亲和力

  摘要：

  制备了一些 2-芳基吡唑并 [1,5-c] [1,3] benzoxazin-5-ones 1 和 5-oxopyrazolo [1,5-c] [1,3] benzoxazin-2-carboxylates 2 并对其进行了生物学评估它们与大鼠皮层膜中苯二氮卓受体 (BZR) 的结合。构效关系研究表明，尽管质子供体 d 和质子受体 a1 都是可选的药效描述子，但为了获得良好的 BZR 亲和力，必须至少存在其中一个。当质子供体 d 不存在时，杂原子受体 a1 在三环核心或 C-2 处的附加取代基中是必要的，以获得亚微摩尔 BZR 亲和力。

  DOI：

  10.1002/ardp.19963291204
• 作为产物：
  描述：

  2'-hydroxy-4-chlorochalkone dibromide 在 一水合肼 、 三乙胺 作用下， 生成 3-(2-Hydroxyphenyl)-5-(4-chlorophenyl)-pyrazol
  参考文献：
  名称：

  Agrawal, Nitin N.; Soni, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2007, vol. 46, # 3, p. 532 - 534

  摘要：

  DOI：

文献信息

• NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
  申请人：Giese Armin

  公开号：US20110293520A1

  公开（公告）日：2011-12-01

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed. Formula (E) wherein X, Y and L are independently nondirectionally selected from —C(R 1 )(R 2 )—, —C(R 3 )═, —N(R 4 )—, —N═, —N + (R 5 )═, —O— and —S—; M and Z are independently nondirectionally selected from formula (I) and formula (II).

  本发明涉及一种由公式（E）表示的化合物。本发明还涉及一种由公式（E）表示的化合物，用于治疗或预防与蛋白质聚集和/或神经退行性疾病相关的疾病。此外，本发明涉及包含本发明化合物的制药和诊断组合物，以及一种试剂盒。此外，本发明还涉及一种成像聚集蛋白沉积物的方法。还公开了一种用于制备可检测标记的本发明化合物的试剂盒。公式（E）中，X、Y和L分别独立地从—C（R1）（R2）—、—C（R3）═、—N（R4）—、—N═、—N+（R5）═、—O—和—S—中非定向选择；M和Z分别独立地从公式（I）和公式（II）中非定向选择。
• Modulators of ATP-Binding Cassette Transporters
  申请人：VanGoor Frederick F.

  公开号：US20100144798A1

  公开（公告）日：2010-06-10

  The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

  本发明涉及ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜调节因子（“CFTR”），以及其组成物和使用这些调节剂的方法。本发明还涉及使用这些调节剂治疗ABC转运蛋白介导的疾病的方法。
• MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
  申请人：Van Goor Frederick F.

  公开号：US20120184583A1

  公开（公告）日：2012-07-19

  The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

  本发明涉及ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜调节器（“CFTR”），以及其组成物和使用这些调节剂的方法。本发明还涉及使用这些调节剂治疗ABC转运蛋白介导的疾病的方法。
• DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
  申请人：Ludwig-Maximilians-Universität München

  公开号：US20160185730A1

  公开（公告）日：2016-06-30

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

  本发明涉及一种由式(E)所表示的化合物。本发明还涉及一种由式(E)所表示的化合物，用于治疗或预防与蛋白质聚集和/或神经退行性疾病有关的疾病。此外，本发明还涉及包含本发明化合物的制药和诊断组合物，以及一种试剂盒。此外，本发明还涉及一种成像聚集蛋白沉积物的方法。还公开了一种用于制备本发明化合物的可检测标记试剂盒。
• Drugs for inhibiting aggregation of proteins invoved in diseases linked to protein aggregation and/or neurodegenerative diseases
  申请人：Ludwig-Maximilians-Universität München

  公开号：EP2687513A1

  公开（公告）日：2014-01-22

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

  本发明涉及一种由式（E）代表的化合物。本发明还涉及一种由式（E）代表的化合物，用于治疗或预防与蛋白质聚集相关的疾病和/或神经退行性疾病。此外，本发明还涉及包含本发明化合物的药物和诊断组合物以及试剂盒。此外，本发明还涉及一种对聚集蛋白沉积物成像的方法。本发明还公开了一种用于制备可检测标记的本发明化合物的试剂盒。